var data={"title":"Beclomethasone (oral inhalation): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Beclomethasone (oral inhalation): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387715?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=beclomethasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (oral inhalation): Drug information&quot;</a> and <a href=\"topic.htm?path=beclomethasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Beclomethasone (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520681\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Qvar;</li>\n      <li>Qvar RediHaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990267\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>QVAR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10481876\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Inhalant (Oral)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482266\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=beclomethasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Doses should be titrated to the lowest effective dose once asthma is controlled: <b>Asthma, maintenance therapy:</b> Children &ge;5 years and Adolescents: Inhalation, oral:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling (Qvar):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5-11 years: Initial: 40 mcg twice daily; maximum dose: 80 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">No previous inhaled corticosteroids: Initial: 40-80 mcg twice daily; maximum dose: 320 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Previous inhaled corticosteroid use: Initial: 40-160 mcg twice daily; maximum dose: 320 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Therapeutic ratio between Qvar and other beclomethasone inhalers (eg, CFC formulations; however, none are currently available in U.S.) has not been established.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: NIH Asthma Guidelines (NAEPP, 2007): HFA formulation (Qvar):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5-11 years: Administer in divided doses:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 80-160 mcg/day (40 mcg/puff: 2-4 puffs/day or 80 mcg/puff: 1-2 puffs/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;160-320 mcg/day (40 mcg/puff: 4-8 puffs/day or 80 mcg/puff: 2-4 puffs/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;320 mcg/day (40 mcg/puff: &gt;8 puffs/day or 80 mcg/puff: &gt;4 puff/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 80-240 mcg/day (40 mcg/puff: 2-6 puffs/day or 80 mcg/puff: 1-3 puffs/day)</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">&quot;Medium&quot; dose: &gt;240-480 mcg/day (40 mcg/puff: 6-12 puffs/day or 80 mcg/puff: 3-6 puffs/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;480 mcg/day (40 mcg/puff: &gt;12 puffs/day or 80 mcg/puff: 6 puffs/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:</i> Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day (or equivalent of other OCS) every 1-2 weeks in adolescents or adults. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal. <b>Note:</b> When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Asthma</b>: Inhalation, oral (doses should be titrated to the lowest effective dose once asthma is controlled):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients previously on bronchodilators only: Initial dose 40-80 mcg twice daily; maximum dose: 320 mcg twice day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients previously on inhaled corticosteroids: Initial dose 40-160 mcg twice daily; maximum dose: 320 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NIH Asthma Guidelines (NIH, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;Low&rdquo; dose: 80-240 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;Medium&rdquo; dose: &gt;240-480 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;High&rdquo; dose: &gt;480 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:</i> Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day (or equivalent of other OCS) every 1-2 weeks. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal. <b>Note:</b> When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520682\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Breath Activated, Inhalation, as dipropionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qvar RediHaler: 40 mcg/actuation (10.6 g); 80 mcg/actuation (10.6 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation, as dipropionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qvar: 40 mcg/actuation (8.7 g); 80 mcg/actuation (8.7 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990269\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005547\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=beclomethasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">QVAR 8.7 g canisters contain 120 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50484713\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">QVAR RediHaler (beclomethasone dipropionate HFA): FDA approved August 2017; availability anticipated in the first quarter of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482267\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Qvar, metered dose inhaler: Canister does not need to be shaken prior to use. Prime canister by spraying twice into the air prior to initial use or if not in use for &gt;10 days. Avoid spraying in face or eyes. Exhale fully prior to bringing inhaler to mouth. Place inhaler in mouth, close lips around mouthpiece, and inhale slowly and deeply while pressing down on the canister with your finger. Remove inhaler and hold breath for approximately 5-10 seconds. Rinse mouth and throat after use to prevent <i>Candida</i> infection. Do not wash or put inhaler in water; mouth piece may be cleaned with a dry tissue or cloth. Discard after the &quot;discard by&quot; date or after labeled number of doses has been used, even if container is not completely empty. Patients using a spacer should inhale immediately due to decreased amount of medication that is delivered with a delayed inspiration. <b>Note:</b> Use of Qvar with a spacer device is not recommended in children &lt;5 years of age due to the decreased amount of medication that is delivered with increasing wait times; patients should be instructed to inhale immediately if using a spacer device.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991738\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Do not use or store near heat or open flame; do not puncture canisters. Exposure to temperatures above 49&ordm;C (120&ordm;F) may cause canister to burst. Never throw container into fire or incinerator. Store on concave end of canister with actuator on top.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10481912\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Long-term (chronic) control of persistent bronchial asthma (FDA approved in ages &ge;5 years and adults); <b>not</b> indicated for the relief of acute bronchospasm. Also used to help reduce or discontinue oral corticosteroid therapy for asthma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991731\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, pain, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (children), nausea, oral candidiasis, vomiting (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea, viral gastroenteritis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, myalgia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Allergic rhinitis, cough, nasopharyngitis, oropharyngeal pain, pharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aggressive behavior, blurred vision, depression, dysgeusia (Tuccori 2011), psychomotor agitation, retinopathy, sleep disorder, suicidal ideation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991662\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to beclomethasone or any component of the formulation; status asthmaticus, or other acute asthma episodes requiring intensive measures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Moderate to severe bronchiectasis requiring intensive measures; untreated fungal, bacterial, or tubercular infections of the respiratory tract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991683\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections (particularly gastroenteritis), or other conditions with severe electrolyte loss. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation (possibly life-threatening); if bronchospasm occurs, discontinue steroid and treat with a fast-acting bronchodilator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (eg, angioedema, bronchospasm, rash, and urticaria) may occur; discontinue use if reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use, if possible, in patients with ocular herpes, active or quiescent respiratory tuberculosis, or untreated viral, fungal, parasitic or bacterial systemic infections. Exposure to chickenpox and measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. If exposure to measles, prophylaxis with pooled intramuscular immunoglobulin may be indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: <i>Candida albicans</i> infections may occur in the mouth and pharynx; if this occurs, treat appropriately while continuing therapy. Patients should be instructed to rinse mouth with water without swallowing after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Short-acting beta<sub>2</sub>-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; blurred vision, increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: A gradual tapering of dose may be required prior to discontinuing therapy; there have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfer to oral inhaler: When transferring to oral inhalation therapy from systemic corticosteroid therapy; previously suppressed allergic conditions (rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions) may be unmasked. Withdraw systemic therapy with gradual tapering of dose; during transition monitor pulmonary function tests (FEV<sub>1</sub> or PEF), beta-agonist use, and asthma symptoms and observe for signs and symptoms of adrenal insufficiency (eg, fatigue, lassitude, weakness, nausea/vomiting, hypotension).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820003\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via inhaled route; reduction in growth velocity is related to dose and duration of exposure; monitor growth. With beclomethasone-HFA (Qvar), the mean reduction in growth velocity was 0.5 cm/year less than that with the previous beclomethasone CFC inhaler formulation. Use of Qvar with a spacer device is not recommended in children &lt;5 years of age due to the decreased amount of medication that is delivered with increasing wait times; patients should be instructed to inhale immediately if using a spacer device.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298819\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991733\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15948&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991658\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG 2008; GINA 2017; Namazy 2016). Pregnant females adequately controlled on beclomethasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females may be preferred (Namazy 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482270\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Check mucous membranes for signs of fungal infection; monitor growth in pediatric patients; monitor IOP with therapy &gt;6 weeks. Monitor for symptoms of asthma, FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991739\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991741\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Within 1 to 2 days in some patients; usually within 1 to 2 weeks; Maximum effect: 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Readily; quickly hydrolyzed by pulmonary esterases to active metabolite (beclomethasone-17-monoproprionate [17-BMP]) during absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Beclomethasone dipropionate (BDP): 20 L; 17-BMP: 424 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: BDP 87%; 17-BMP: 94% to 96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: BDP is a pro-drug (inactive); undergoes rapid conversion to 17-BMP during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QVAR: BDP: 0.5 hours; 17-BMP: 2.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RediHaler: BDP: 2 minutes; 17-BMP: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QVAR: BDP: 0.5 hours; 17-BMP: 0.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RediHaler: BDP: 2 minutes; 17-BMP: 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primary route of excretion is via feces (~60%); &lt;10% to 12% of oral dose excreted in urine as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482272\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Qvar: Does not contain chlorofluorocarbons (CFCs), uses hydrofluoroalkane (HFA) as the propellant; is a solution formulation; uses smaller-size particles which results in a higher percent of drug delivered to the respiratory tract and lower recommended doses than other products. An open-label, randomized, multicenter, 12-month study in 300 asthmatic children 5-11 years of age indicated that QVAR provided long-term control of asthma at approximately half the dose compared with a CFC propelled beclomethasone MDI and spacer (Pedersen, 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991814\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Qvar RediHaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/ACT (10.6 g): $203.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/ACT (10.6 g): $271.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Qvar Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/ACT (8.7 g): $203.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/ACT (8.7 g): $271.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961956\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AeroBec (DK, NO, SE);</li>\n      <li>Aerocort (MY);</li>\n      <li>Aerovent (IN);</li>\n      <li>Asmabec Clickhaler (FR, IE);</li>\n      <li>Beclasone (UA);</li>\n      <li>Beclate (ET, ZA, ZW);</li>\n      <li>Beclate Aquanase (ZW);</li>\n      <li>Beclazone (BH, CY, HK, IE, KW, LB, MT, NZ, SA, TR, VN);</li>\n      <li>Beclo-Asma (CU, ES);</li>\n      <li>Beclod (BD);</li>\n      <li>Becloforte (AE, BH, JO, QA, SA);</li>\n      <li>Beclohale (LK);</li>\n      <li>Beclomet (DK, FI, NO, SE, SG, TH);</li>\n      <li>Beclomin (PK);</li>\n      <li>Beclone (FR);</li>\n      <li>Beclophar (GB, IE);</li>\n      <li>Beclotis (ET);</li>\n      <li>Beclovent Inhalador (CO);</li>\n      <li>Beconase (VE);</li>\n      <li>Becotide (AE, BH, CH, CN, CR, CZ, DO, EG, GT, HN, IE, JO, NI, PA, QA, SA, SV);</li>\n      <li>Beklofort Evohaler (UA);</li>\n      <li>Bekotid Evohaler (UA);</li>\n      <li>Bemedrex (FR);</li>\n      <li>Bronconox (CO);</li>\n      <li>Bronconox Forte (CO);</li>\n      <li>Clenil (AE, BR, CN, IT, MT, SG, TW);</li>\n      <li>Clenil Forte (CY);</li>\n      <li>Destap FS (CL);</li>\n      <li>Eclosynt (CO);</li>\n      <li>Ecobec (BG, EE, PT);</li>\n      <li>Ibicar (PH);</li>\n      <li>Meclonate (VN);</li>\n      <li>Propavent (AR);</li>\n      <li>Qvar (AU, CH, CR, DO, FR, GB, GT, HN, HR, IE, IL, MY, NI, NZ, PA, PT, SV);</li>\n      <li>Respocort (NZ);</li>\n      <li>Steradin HFA (BD);</li>\n      <li>Ventolair (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    QVAR [package insert], Horsham, PA:Teva Respiratory, LLC: 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pedersen S, Warner J, Wahn U, et al, &ldquo;Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extra Fine and Conventional Aerosols in Children,&rdquo; <i>Pediatrics</i>, 2002, 109(6), http://www.pediatrics.org/cgi/content/full/109/6/e92. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/12042586/pubmed\" target=\"_blank\" id=\"12042586\">12042586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tinkelman DG, Reed CE, Nelson HS, et al, &ldquo;Aerosol Beclomethasone Dipropionate Compared With Theophylline as Primary Treatment of Chronic, Mild-to-Moderately Severe Asthma in Children,&rdquo; <i>Pediatrics</i>, 1993, 92(1):64-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/8516087/pubmed\" target=\"_blank\" id=\"8516087\">8516087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wyatt R, Waschek J, Weinberger M, et al, &ldquo;Effects of Inhaled Beclomethasone Dipropionate and Alternate-Day Prednisone on Pituitary-Adrenal Function in Children With Chronic Asthma,&rdquo; <i>N Engl J Med</i>, 1978, 299(25):1387-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-oral-inhalation-pediatric-drug-information/abstract-text/362207/pubmed\" target=\"_blank\" id=\"362207\">362207</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15948 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520681\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7990267\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10481876\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10482266\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520682\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F7990269\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005547\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50484713\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10482267\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7991738\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10481912\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7991731\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7991662\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7991683\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820003\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298819\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7991733\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7991658\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10482270\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7991739\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F7991741\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10482272\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7991814\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961956\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15948|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=beclomethasone-oral-inhalation-drug-information\" class=\"drug drug_general\">Beclomethasone (oral inhalation): Drug information</a></li><li><a href=\"topic.htm?path=beclomethasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Beclomethasone (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}